Violation Tracker Industry Summary Page
Industry:
pharmaceuticals
Penalty Total since 2000:
$71,670,170,863
Number of Records:
968
Note:
The totals include only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. The totals are adjusted to account for the fact that each parent's entries may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. They are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the individual records list below.
| Top 10 Parent Companies | Total Penalty $ | Number of Records |
|---|---|---|
| Purdue Pharma | $19,124,272,787 | 11 |
| Johnson & Johnson | $9,248,447,763 | 59 |
| GlaxoSmithKline | $7,837,200,258 | 35 |
| Merck | $5,548,085,581 | 78 |
| Pfizer | $4,660,896,333 | 71 |
| AbbVie | $3,203,142,507 | 49 |
| Teva Pharmaceutical Industries | $2,735,215,328 | 53 |
| Novartis | $2,526,283,570 | 39 |
| Mallinckrodt | $1,755,367,478 | 20 |
| Bristol-Myers Squibb | $1,704,939,820 | 39 |
Individual Penalty Records:
Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
| Company | Parent | Primary Offense Type | Year | Agency |
Penalty Amount |
|---|---|---|---|---|---|
| Mylan Laboratories et al. | Viatris | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*) $108,000,000 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
| Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Mylan Laboratories, Inc. | Viatris | consumer protection violation | 2000 | FTC | $100,000,000 |
| Mallinckrodt ARD Inc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | FTC | $100,000,000 |
| Astellas Pharma US Inc. | Astellas Pharma | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
| Bristol-Myers Squibb Co. | Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $100,000,000 |
| Mallinckrodt plc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | MULTI-AG | (*) $100,000,000 |
| Novartis | Novartis | wage and hour violation | 2012 | private lawsuit-federal | $99,000,000 |
| Gilead Sciences, Inc. | Gilead Sciences | False Claims Act and related | 2020 | DOJ_CIVIL | $97,000,000 |
| Aventis Pharmaceutical Inc. | Sanofi | False Claims Act and related | 2009 | DOJ_CIVIL | $95,500,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $95,000,000 |
| Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*) $91,602,000 |
| GlaxoSmithKline LLC | GlaxoSmithKline | drug or medical equipment safety violation | 2012 | MULTI-AG | $90,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $88,258,694 |
| Scios Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
| Teva Pharmaceuticals | Teva Pharmaceutical Industries | Controlled Substances Act violation | 2019 | OK-AG | $85,000,000 |
| Depuy Orthopaedics Inc. | Johnson & Johnson | False Claims Act and related | 2007 | USAO | $84,700,000 |
| Novartis Pharmaceuticals Corporation | Novartis | kickbacks and bribery | 2015 | MULTI-AG | (*) $83,129,754 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | False Claims Act and related | 2021 | USAO | $75,000,000 |
| Bristol Myers Squibb Co. | Bristol-Myers Squibb | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | False Claims Act and related | 2006 | MULTI-AG | $70,000,000 |
| Watson Pharmaceuticals | AbbVie | False Claims Act and related | 2011 | MULTI-AG | $70,000,000 |
| Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | consumer protection violation | 2019 | CA-AG | $69,000,000 |
| AstraZeneca Pharmaceuticals | AstraZeneca | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | $68,500,000 |
| OSI Pharmaceuticals LLC | Astellas Pharma | False Claims Act and related | 2016 | DOJ_CIVIL | $67,000,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
| LifeScan Inc. | Johnson & Johnson | drug or medical equipment safety violation | 2000 | USAO | $60,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | False Claims Act and related | 2010 | MULTI-AG | (*) $60,000,000 |
| Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $60,000,000 |
| Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $60,000,000 |
| Novo Nordisk Inc. | Novo Holdings A/S | False Claims Act and related | 2017 | DOJ_CIVIL | $58,650,000 |
| Merck & Co. | Merck | consumer protection violation | 2008 | MULTI-AG | $58,000,000 |
| Jazz Pharmaceuticals plc | Jazz Pharmaceuticals | False Claims Act and related | 2019 | DOJ_CIVIL | $57,000,000 |
| Shire Pharmaceuticals LLC | Takeda Pharmaceutical | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
| Pfizer Inc. | Pfizer | drug or medical equipment safety violation | 2012 | FDA | $55,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
| GlaxoSmithKline LLC | GlaxoSmithKline | False Claims Act and related | 2019 | IL-AG | $54,653,931 |
| Salix Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2016 | USAO | $54,000,000 |
| Lundbeck LLC | Lundbeck | False Claims Act and related | 2019 | DOJ_CIVIL | $52,600,000 |
| Endo Health Solutions | Endo International | off-label or unapproved promotion of medical products | 2021 | NY-AG | $50,000,000 |
| Johnson & Johnson | Johnson & Johnson | False Claims Act and related | 2019 | IL-AG | $49,505,368 |
| Merck & Co., Inc. | Merck | benefit plan administrator violation | 2011 | private lawsuit-federal | $49,500,000 |
| Pfizer Corporation | Pfizer | False Claims Act and related | 2002 | DOJ_CIVIL | $49,000,000 |
| Johnson & Johnson | Johnson & Johnson | Foreign Corrupt Practices Act | 2011 | SEC | $48,600,000 |
| Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | CA-AG | $47,498,000 |
| SmithKline Beecham | GlaxoSmithKline | False Claims Act and related | 2003 | DOJ_CIVIL | $47,000,000 |
| AstraZeneca LP | AstraZeneca | False Claims Act and related | 2015 | DOJ_CIVIL | $46,500,000 |
| AstraZeneca LP | AstraZeneca | False Claims Act and related | 2015 | MULTI-AG | (*) $46,500,000 |
| Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
| Bausch Health | Bausch Health | accounting fraud or deficiencies | 2020 | SEC | $45,000,000 |
| Serono Laboratories Inc. | Merck KGaA (EMD) | False Claims Act and related | 2011 | DOJ_CIVIL | $44,300,000 |
| EMD Serono, Inc. | Merck KGaA (EMD) | False Claims Act and related | 2011 | MULTI-AG | (*) $44,300,000 |
| Elan Corp. | Perrigo | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $43,399,040 |
| Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $42,900,000 |
| Alpharma Inc. | Pfizer | False Claims Act and related | 2010 | DOJ_CIVIL | $42,500,000 |
| Kos Pharmaceuticals | AbbVie | kickbacks and bribery | 2010 | FDA | $41,500,000 |
| Briston-Myers Squibb | Bristol-Myers Squibb | benefit plan administrator violation | 2005 | private lawsuit-federal | $41,220,000 |
| Pfizer Inc. | Pfizer | False Claims Act and related | 2019 | IL-AG | $41,047,101 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | drug or medical equipment safety violation | 2011 | MULTI-AG | $40,750,000 |
| Andrx Corporation | AbbVie | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $40,000,000 |
| Aventis Pharmaceutical Inc. | Sanofi | False Claims Act and related | 2009 | MULTI-AG | (*) $40,000,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $40,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | False Claims Act and related | 2003 | MULTI-AG | $40,000,000 |
| Daiichi Sankyo Inc. | Daiichi Sankyo | False Claims Act and related | 2015 | DOJ_CIVIL | $39,000,000 |
| Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals | Endo International | drug or medical equipment safety violation | 2015 | USAO | $39,000,000 |
| Daiichi Sankyo, Inc. | Daiichi Sankyo | False Claims Act and related | 2015 | MULTI-AG | $39,000,000 |
| Endo Health Solutions | Endo International | False Claims Act and related | 2015 | MULTI-AG | (*) $39,000,000 |
| Alere Inc. | Abbott Laboratories | False Claims Act and related | 2021 | DOJ_CIVIL | $38,750,000 |
| Forest Laboratories and Forest Pharmaceuticals | AbbVie | False Claims Act and related | 2016 | DOJ_CIVIL | $38,000,000 |
| InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
| Organon USA Inc | Organon & Co. | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $36,000,000 |
| Mallinckrodt LLC | Mallinckrodt | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
| Aegerion Pharmaceuticals Inc. | Amryt Pharma | drug or medical equipment safety violation | 2017 | DOJ_CIVIL | $35,000,000 |
| Pfizer | Pfizer | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
| UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
| Genentech Inc. | Roche | False Claims Act and related | 2016 | DOJ_CIVIL | $33,500,000 |
| ISTA Pharmaceuticals, Inc. | Bausch Health | False Claims Act and related | 2013 | DOJ_CIVIL | $33,500,000 |
| OSI Pharmaceuticals LLC | Astellas Pharma | False Claims Act and related | 2016 | DOJ_CIVIL | $33,500,000 |
| Watson, Inc. | AbbVie | False Claims Act and related | 2018 | MS-AG | $33,408,547 |
| Alere Inc. | Abbott Laboratories | False Claims Act and related | 2018 | DOJ_CIVIL | $33,200,000 |
| Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2017 | MULTI-AG | $33,000,000 |
| Genzyme Corporation | Sanofi | drug or medical equipment safety violation | 2015 | FDA | $32,587,439 |
| Abbott Laboratories | Abbott Laboratories | False Claims Act and related | 2003 | MULTI-AG | (*) $32,500,000 |
| Organon | Organon & Co. | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $31,000,000 |
| Schering-Plough | Merck | False Claims Act and related | 2008 | MO-AG | $31,000,000 |
| LifeScan, Inc. | Johnson & Johnson | drug or medical equipment safety violation | 2003 | MULTI-AG | $30,600,000 |
| Sandoz, Inc. | Novartis | False Claims Act and related | 2011 | MS-AG | $30,110,618 |
| Mylan N.V. | Viatris | investor protection violation | 2019 | SEC | $30,000,000 |
| Wyeth-Ayerst Laboratories Division | Pfizer | drug or medical equipment safety violation | 2000 | FDA | $30,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
| Pharmacia Corporation | Viatris | False Claims Act and related | 2013 | WI-AG | $29,453,247 |
| Eli Lilly and Company | Eli Lilly | Foreign Corrupt Practices Act | 2012 | SEC | $29,398,734 |
| Actavis Mid-Atlantic, LLC and Actavis Elizabeth, LLC | Teva Pharmaceutical Industries | False Claims Act and related | 2011 | TX-AG | $29,230,000 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $29,000,000 |
| Abbott Laboratories Inc. | AbbVie | False Claims Act and related | 2008 | TX-AG | $28,000,000 |
